Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

High-dose donepezil (23 mg/day) for the treatment of moderate and severe Alzheimer's disease: drug profile and clinical guidelines.

Cummings JL, Geldmacher D, Farlow M, Sabbagh M, Christensen D, Betz P.

CNS Neurosci Ther. 2013 May;19(5):294-301. doi: 10.1111/cns.12076. Epub 2013 Mar 6. Review.

PMID:
23462265
2.

Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study.

Farlow MR, Salloway S, Tariot PN, Yardley J, Moline ML, Wang Q, Brand-Schieber E, Zou H, Hsu T, Satlin A.

Clin Ther. 2010 Jul;32(7):1234-51. doi: 10.1016/j.clinthera.2010.06.019.

3.

Higher-dose (23 mg/day) donepezil formulation for the treatment of patients with moderate-to-severe Alzheimer's disease.

Christensen DD.

Postgrad Med. 2012 Nov;124(6):110-6. doi: 10.3810/pgm.2012.11.2589. Review.

PMID:
23322144
4.

Donepezil for dementia due to Alzheimer's disease.

Birks J, Harvey RJ.

Cochrane Database Syst Rev. 2006 Jan 25;(1):CD001190. Review.

PMID:
16437430
5.

Cholinesterase inhibitors for Alzheimer's disease.

Birks J.

Cochrane Database Syst Rev. 2006 Jan 25;(1):CD005593. Review.

6.
7.

Safety and tolerability of donepezil at doses up to 20 mg/day: results from a pilot study in patients with Alzheimer's disease.

Doody RS, Corey-Bloom J, Zhang R, Li H, Ieni J, Schindler R.

Drugs Aging. 2008;25(2):163-74.

PMID:
18257603
8.

Donepezil for dementia due to Alzheimer's disease.

Birks JS, Harvey R.

Cochrane Database Syst Rev. 2003;(3):CD001190. Review. Update in: Cochrane Database Syst Rev. 2006;(1):CD001190.

PMID:
12917900
9.

Efficacy and safety of donepezil 23 mg versus donepezil 10 mg for moderate-to-severe Alzheimer's disease: a subgroup analysis in patients already taking or not taking concomitant memantine.

Doody RS, Geldmacher DS, Farlow MR, Sun Y, Moline M, Mackell J.

Dement Geriatr Cogn Disord. 2012;33(2-3):164-73. doi: 10.1159/000338236. Epub 2012 May 10.

PMID:
22572767
10.

Donepezil for mild and moderate Alzheimer's disease.

Birks J S, Melzer D.

Cochrane Database Syst Rev. 2000;(2):CD001190. Review. Update in: Cochrane Database Syst Rev. 2000;(4):CD001190.

PMID:
10796620
11.

Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial.

Feldman H, Gauthier S, Hecker J, Vellas B, Xu Y, Ieni JR, Schwam EM; Donepezil MSAD Study Investigators Group.

Int J Geriatr Psychiatry. 2005 Jun;20(6):559-69.

PMID:
15920715
12.

Donepezil and memantine for moderate-to-severe Alzheimer's disease.

Howard R, McShane R, Lindesay J, Ritchie C, Baldwin A, Barber R, Burns A, Dening T, Findlay D, Holmes C, Hughes A, Jacoby R, Jones R, Jones R, McKeith I, Macharouthu A, O'Brien J, Passmore P, Sheehan B, Juszczak E, Katona C, Hills R, Knapp M, Ballard C, Brown R, Banerjee S, Onions C, Griffin M, Adams J, Gray R, Johnson T, Bentham P, Phillips P.

N Engl J Med. 2012 Mar 8;366(10):893-903. doi: 10.1056/NEJMoa1106668.

13.

Response to rivastigmine or donepezil in Alzheimer's patients with symptoms suggestive of concomitant Lewy body pathology.

Touchon J, Bergman H, Bullock R, Rapatz G, Nagel J, Lane R.

Curr Med Res Opin. 2006 Jan;22(1):49-59. Erratum in: Curr Med Res Opin. 2006 Aug;22(8):1451.

PMID:
16393430
14.

DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease - a multicentre RCT.

Jones R, Sheehan B, Phillips P, Juszczak E, Adams J, Baldwin A, Ballard C, Banerjee S, Barber B, Bentham P, Brown R, Burns A, Dening T, Findlay D, Gray R, Griffin M, Holmes C, Hughes A, Jacoby R, Johnson T, Jones R, Knapp M, Lindesay J, McKeith I, McShane R, Macharouthu A, O'Brien J, Onions C, Passmore P, Raftery J, Ritchie C, Howard R; DOMINO-AD team.

Trials. 2009 Jul 24;10:57. doi: 10.1186/1745-6215-10-57.

15.

A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.

Tariot PN, Cummings JL, Katz IR, Mintzer J, Perdomo CA, Schwam EM, Whalen E.

J Am Geriatr Soc. 2001 Dec;49(12):1590-9.

PMID:
11843990
16.

Donepezil and rivastigmine in the treatment of Alzheimer's disease: a best-evidence synthesis of the published data on their efficacy and cost-effectiveness.

Wolfson C, Oremus M, Shukla V, Momoli F, Demers L, Perrault A, Moride Y.

Clin Ther. 2002 Jun;24(6):862-86; discussion 837. Review.

PMID:
12117079
17.

Perspectives in the management of Alzheimer's disease: clinical profile of donepezil.

Rogers SL.

Dement Geriatr Cogn Disord. 1998;9 Suppl 3:29-42. Review.

PMID:
9853200
18.

Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial.

Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I; Memantine Study Group.

JAMA. 2004 Jan 21;291(3):317-24.

PMID:
14734594
19.

Effectiveness of open-label donepezil treatment in patients with Alzheimer's disease discontinuing memantine monotherapy.

Sakka P, Tsolaki M, Hort J, Hager K, Soininen H, López Pousa S, Li C, Schwam E.

Curr Med Res Opin. 2007 Dec;23(12):3153-65.

PMID:
17988434
20.

Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer's disease.

Farlow M, Veloso F, Moline M, Yardley J, Brand-Schieber E, Bibbiani F, Zou H, Hsu T, Satlin A.

BMC Neurol. 2011 May 25;11:57. doi: 10.1186/1471-2377-11-57.

Items per page

Supplemental Content

Write to the Help Desk